Jiangsu HengRui Medicine Co., Ltd.
730
88
116
283
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
4.8%
35 terminated/withdrawn out of 730 trials
89.0%
+2.5% vs industry average
19%
139 trials in Phase 3/4
5%
14 of 283 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (730)
A Clinical Study on the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-1049 in Patients With Advanced Solid Tumors
Role: lead
SHR-1701 in Combination With Irinotecan Liposome (II) for Second-line Treatment of ESCC After Immunotherapy
Role: collaborator
A Phase II Clinical Study of FH-006 for Injection Combined With Other Anticancer Therapies in Subjects With Lung Cancer
Role: lead
Study on the Mass Balance of [14C]HRS-9190 for Injection in Healthy Participants
Role: lead
A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer
Role: lead
A Clinical Study Comparing the Relative Bioavailability and Safety of SHR-3167 Injection
Role: lead
Safety and Efficacy of HRS-9190 Compared to Rocuronium for Bolus Maintenance in Adults
Role: lead
Pharmacokinetics Impact of HRS-8427 on Bupropion and Midazolam in Healthy Subjects
Role: lead
A Study Comparing Safety and Efficacy of SHR-3167 Fixed-Dose Titration and Individualized-Dose Titration in Adults With Type 2 Diabetes Inadequately Controlled With Oral Antihyperglycemic Agents
Role: lead
A Trial of Tegileridine Fumarate Lnjection for Prolonged Mechanical Ventilation Abirritation in the Intensive Care Unit (ICU)
Role: lead
A Study of HRS7415 Tablets in Patients With Advanced Malignant Tumors
Role: lead
A Study to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Primary IgA Nephropathy.
Role: lead
A Study of Bupivacaine Liposome Injection in the Treatment of Pain After Thoracoscopic Surgery
Role: lead
A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer
Role: lead
A Phase I Clinical Study of the Safety， Tolerability，Pharmacokinetics, and Initial Efficacy of HRS-6209 Monotherapy in Patients With Advanced Solid Tumors
Role: lead
A Study to Evaluate the Safety, Tolerability and Dose-Response Relationship of HRS-9190 in Healthy Subjects
Role: lead
A Study of HRS-2329 in Participants With Advanced Solid Tumors Harboring RAS Mutations or Amplifications
Role: lead
Efficacy and Safety of Ivarmacitinib Monotherapy in the Treatment of csDMARDs-IR Rheumatoid Arthritis
Role: collaborator
A Study of SHR-1210 in Combination With Apatinib in Advanced Non-Small Cell Lung Cancer(NSCLC)
Role: lead
A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer
Role: lead